| Drug General Information |
| Drug ID |
D03BOZ
|
| Former ID |
DNC004074
|
| Drug Name |
RS-130830
|
| Drug Type |
Small molecular drug
|
| Indication |
HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10:B17.1, B18.2]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H20ClNO6S
|
| Canonical SMILES |
C1COCCC1(CS(=O)(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C(=O)N<br />O
|
| InChI |
1S/C19H20ClNO6S/c20-14-1-3-15(4-2-14)27-16-5-7-17(8-6-16)28(24,25)13-19(18(22)21-23)9-11-26-12-10-19/h1-8,23H,9-13H2,(H,21,22)
|
| InChIKey |
ROSNVSQTEGHUKU-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Stromelysin-1 |
Target Info |
Inhibitor |
[2]
|
|---|
| 72 kDa type IV collagenase |
Target Info |
Inhibitor |
[2]
|
| MMP-9 |
Target Info |
Inhibitor |
[2]
|
| Collagenase 3 |
Target Info |
Inhibitor |
[2]
|
| Interstitial collagenase |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
TNF signaling pathway
|
|
Transcriptional misregulation in cancer
|
|
Rheumatoid arthritishsa04670:Leukocyte transendothelial migration
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
Bladder cancerhsa04668:TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Hepatitis B
|
|
MicroRNAs in cancer
|
|
Bladder cancerhsa03320:PPAR signaling pathway
|
|
Bladder cancer
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
IL4 Signaling PathwayNetPath_22:Leptin Signaling Pathway
|
|
TCR Signaling Pathway
|
|
ID Signaling PathwayNetPath_5:ID Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
TNFalpha Signaling PathwayNetPath_13:IL1 Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
PANTHER Pathway
|
Plasminogen activating cascade
|
|
CCKR signaling map STP00004:Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathway
|
|
CCKR signaling map STP00004:Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascadeP00004:Alzheimer disease-presenilin pathway
|
|
Pathway Interaction Database
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
p75(NTR)-mediated signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalinglysophospholipid_pathway:LPA receptor mediated events
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Direct p53 effectors
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
|
Syndecan-2-mediated signaling eventslysophospholipid_pathway:LPA receptor mediated events
|
|
Validated targets of C-MYC transcriptional activation
|
|
CXCR4-mediated signaling events
|
|
Syndecan-4-mediated signaling events
|
|
AP-1 transcription factor network
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Syndecan-1-mediated signaling events
|
|
FGF signaling pathwayupa_upar_pathway:Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalingendothelinpathway:Endothelins
|
|
Glucocorticoid receptor regulatory network
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Assembly of collagen fibrils and other multimeric structures
|
|
EGFR Transactivation by GastrinR-HSA-1442490:Collagen degradation
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
|
|
Assembly of collagen fibrils and other multimeric structuresR-HSA-1442490:Collagen degradation
|
|
Basigin interactions
|
|
WikiPathways
|
Activation of Matrix Metalloproteinases
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Oncostatin M Signaling Pathway
|
|
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases
|
|
AGE/RAGE pathway
|
|
Matrix MetalloproteinasesWP474:Endochondral Ossification
|
|
IL1 and megakaryotyces in obesity
|
|
Mammary gland development pathway - Involution (Stage 4 of 4)
|
|
Degradation of collagen
|
|
Spinal Cord Injury
|
|
TWEAK Signaling Pathway
|
|
Angiogenesis
|
|
Osteopontin Signaling
|
|
Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway
|
|
Bladder Cancer
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Cell surface interactions at the vascular wall
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010620) |
|---|
| REF 2 | Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). |
|---|
